Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

被引:1
作者
James R. Spalding
Joel Hay
机构
[1] Astellas Pharma US,Department of Pharmaceutical Economics and Policy
[2] School of Pharmacy,undefined
[3] University of Southern California,undefined
来源
PharmacoEconomics | 2006年 / 24卷
关键词
Rheumatoid Arthritis; Methotrexate; Infliximab; Etanercept; Adalimumab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1221 / 1232
页数:11
相关论文
共 85 条
[1]  
Hochberg M(2002)Guidelines for the management of rheumatoid arthritis: 2002 update Arthritis Rheum 46 328-346
[2]  
Cooper N(1981)Adult and juvenile rheumatoid arthritis: current epidemiologic concepts Epidemiol Rev 3 27-44
[3]  
Arnett F(2000)Economic burden of rheumatoid arthritis: a systematic review Rheumatology 39 28-33
[4]  
Edworthy S(1988)The American Rheumatology Association 1987 revised criteria for classification or rheumatoid arthritis Arthritis Rheum 31 315-324
[5]  
Bloch D(2000)Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins Arthritis Rheum 43 30-37
[6]  
MacGregor A(2001)Association between rheumatoid arthritis and polymorphisms of tumor necrosis factor II, but not tumor necrosis factor in Caucasians Arthritis Rheum 44 61-65
[7]  
Schneider H(1996)The effectiveness of early treatment with “second-line” anti-rheumatic drugs Ann Intern Med 124 699-707
[8]  
Rigby A(2003)New antibody approved for the treatment of rheumatoid arthritis J Am Pharm Assoc 43 327-328
[9]  
Barton A(2004)Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 3432-3443
[10]  
John S(2002)Etanercept vs MTX in patients with early RA Arthritis Rheum 46 1443-1450